Skip to main content
Clinical Trials/NCT05460715
NCT05460715
Active, not recruiting
Not Applicable

Prospective Multicentre Study to Evaluate the Long-term Performance of Anteverted Femoral Stems in Total Hip Arthroplasty

Medacta International SA1 site in 1 country300 target enrollmentJuly 30, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arthrosis
Sponsor
Medacta International SA
Enrollment
300
Locations
1
Primary Endpoint
Evaluate the 10-year survival of the anteverted Quadra-P stem
Status
Active, not recruiting
Last Updated
7 months ago

Overview

Brief Summary

This is a Post-Marketing Surveillance of Quadra-P anteverted stem prosthesis.

Detailed Description

The primary objective of this study is to evaluate the 10-year survival of the anteverted Quadra-P stem in patients operated for primary total hip arthroplasty, according to the inclusion criteria. Secondary objectives: * To assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years. * Assess radiological performance by standard radiographic examination performed preoperatively, postoperatively before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years. * Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery. * Assessment of functional recovery by gait analysis study * Collect the rate of complications throughout the course of the study

Registry
clinicaltrials.gov
Start Date
July 30, 2021
End Date
July 1, 2032
Last Updated
7 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects suffering from primary hip arthrosis, post-traumatic arthrosis, dysplasia or avascular necrosis of the femoral head, rheumatoid arthritis
  • Adult subjects between 18 and 75 years of age on the date of surgery
  • Subjects eligible for primary total hip arthroplasty surgery for whom the anterior Quadra-P femoral component will be implanted according to the indications for use of the implant
  • Subjects who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to surgery.
  • For the anatomical-functional subgroup:
  • \- Adult subjects aged between 18 and 65 years at the date of surgery who have agreed to undergo the gait analysis study.

Exclusion Criteria

  • Subjects with acute or chronic infection
  • Subjects with a femoral neck fracture
  • Subjects with mental conditions that impair their ability to consent to the study, to complete required questionnaires or to complete follow-up visits
  • Subjects with severe deformities, at the discretion of the surgeon
  • Subjects with metabolic disorders that may involve bone metabolism for which an uncemented implant would be contraindicated
  • Subjects with muscular atrophy or neuromuscular diseases
  • Subjects allergic to the materials used during surgery
  • Subjects unable or unwilling to provide consent for participation in the study
  • Any other condition not mentioned in the inclusion criteria

Outcomes

Primary Outcomes

Evaluate the 10-year survival of the anteverted Quadra-P stem

Time Frame: 10 years

% survival rate

Secondary Outcomes

  • Assessing the patient's perception of the prosthetic joint(at 3 months and at 1, 2, 5, 7 and 10 years after surgery.)
  • Collect the rate of complications(at pre-op, immediate post-op, 3 months, 1, 2, 5, 7 and 10 years.)
  • Assess clinical performance(at 3 months, 1, 2, 5, 7 and 10 years.)
  • Assessment of functional recovery(at pre-op, 3 months and at 1 year after surgery.)
  • Assess radiological performance(at pre-op, 3 months, 1, 2, 5, 7 and 10 years.)

Study Sites (1)

Loading locations...

Similar Trials